Filana Therapeutics (FLNA) Accumulated Expenses (2010 - 2026)

Filana Therapeutics' Accumulated Expenses history runs 17 years deep, the most recent figure standing at $39.3 million for Q2 2026.

• In Q2 2026, Accumulated Expenses fell 8.25% year-over-year to $39.3 million; the TTM figure through Jun 2026 stood at $39.3 million (down 8.25% YoY), while the FY2025 annual figure was $41.6 million, up 444.12% from the prior year.
• Accumulated Expenses for Q2 2026 stood at $39.3 million, roughly flat from $39.2 million in the prior quarter.
• The five-year high for Accumulated Expenses was $52.6 million in Q2 2024, with the low at $2.9 million in Q1 2022.
• The 5-year median for Accumulated Expenses is $9.5 million (2023), against an average of $21.4 million.
• Peak annual rise in Accumulated Expenses reached 646.05% in 2024, while the deepest fall reached 27.61% in 2024.
• Filana Therapeutics' Accumulated Expenses stood at $4.0 million in 2022, then soared by 163.21% to $10.6 million in 2023, then declined by 27.61% to $7.7 million in 2024, then jumped by 444.12% to $41.6 million in 2025, then slipped by 5.66% to $39.3 million in 2026.
• Business Quant data shows FLNA's Accumulated Expenses at $39.3 million in Q2 2026, $39.2 million in Q1 2026, and $41.6 million in Q4 2025.